5-tert-butyl-2,3-dimethoxytoluene | 34582-28-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-tert-butyl-2,3-dimethoxytoluene
• 英文别名: 3-Methyl-5-tert-butyl-veratrol；5-Tert-butyl-1,2-dimethoxy-3-methylbenzene
• CAS: 34582-28-0
• 化学式: C₁₃H₂₀O₂
• 分子量: 208.301
• InChiKey: ADJNLBAWYWNJTH-UHFFFAOYSA-N

物化性质

• 沸点：
  266.5±40.0 °C(Predicted)
• 密度：
  0.945±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-叔丁基-3-甲基-1,2-苯二酚 、 碘甲烷 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 以73%的产率得到5-tert-butyl-2,3-dimethoxytoluene
  参考文献：
  名称：

  Synthesis of Linear Oligo(catechol) Ligands for the Metal Directed Self-Assembling of Helicates

  摘要：

  不同取代基、连接间隔长度和儿茶酚单位数量的寡(儿茶酚)系统1-4的合成是通过使用各种偶联反应（如Wurtz反应、Glaser-Eglinton反应和Stephens-Castro反应）实现的。为了做到这一点，已经开发了制备构建块的方法，包括从简单的儿茶酚（苯-1,2-二醇）衍生物出发的2,3-二甲氧基苯基溴化物5、2,3-二甲氧基苯乙炔（17）或1,4-二溴-2,3-二甲氧基苯（23）。

  DOI：

  10.1055/s-1996-4188

文献信息

• Compounds Useful for Promoting Protein Degradation and Methods Using Same
  申请人：Yale University

  公开号：US20160022642A1

  公开（公告）日：2016-01-28

  The present description includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In certain embodiments, the description includes a compound comprising a protein degradation moiety covalently bound to a linker, wherein the ClogP of the compound is equal to or higher than 1.5. The target protein contemplated within the description comprises an androgen receptor. Compounds of the present description may be used to treat disease states wherein protein degradation is a viable therapeutic approach, such as cancer or any sort of oxidative stress disease state.

  本描述包括作为目标蛋白质降解剂的化合物，其中降解与目标蛋白质的类别或其定位无关。在某些实施例中，描述包括一种化合物，其中蛋白质降解基团与连接剂共价结合，该化合物的ClogP等于或高于1.5。描述中考虑的目标蛋白质包括雄激素受体。本描述的化合物可用于治疗蛋白质降解是可行治疗方法的疾病状态，如癌症或任何一种氧化应激疾病状态。
• METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS
  申请人：Wilson Troy Edward

  公开号：US20110269779A1

  公开（公告）日：2011-11-03

  The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating signal transduction by certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PB kinase in an ocular tissue. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

  本发明提供了能够调节特定蛋白激酶（如mTor、酪氨酸激酶和/或脂质激酶如PB激酶）在眼组织中的信号传导的化学实体或化合物以及其制药组合物。本发明还提供了利用这些组合物调节这些激酶中的一个或多个的活性的方法，特别是用于治疗应用。
• SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES
  申请人：Cooper Robin

  公开号：US20090062270A1

  公开（公告）日：2009-03-05

  The present invention provides methods of treating or preventing autoimmune diseases with spiro 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

  本发明提供了使用螺环2,4-嘧啶二胺化合物治疗或预防自身免疫性疾病的方法，以及治疗、预防或缓解与此类疾病相关症状的方法。可以使用该化合物治疗或预防的自身免疫性疾病的具体例子包括类风湿性关节炎及/或其相关症状、系统性红斑狼疮及/或其相关症状和多发性硬化及/或其相关症状。
• Kinase Antagonists
  申请人：Knight Zachary A.

  公开号：US20110301144A1

  公开（公告）日：2011-12-08

  The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tyrosine kinase, PI3 kinase and mTOR, or PI33 kinase, mTOR and tyrosine kinase.

  本发明提供了一种新型化合物，它们是PI3激酶、PI3激酶和酪氨酸激酶、PI3激酶和mTOR或PI33激酶、mTOR和酪氨酸激酶的拮抗剂。
• NON-STEROIDAL LIGANDS FOR THE GLUCOCORTICOID RECEPTOR, COMPOSITIONS AND USES THEREOF
  申请人：Scanlan Thomas S.

  公开号：US20110218225A1

  公开（公告）日：2011-09-08

  The invention provides non-steroidal ligands for the glucocorticoid receptor, methods for making non-steroidal ligands of the glucocorticoid receptor, compositions of non-steroidal ligands of the glucocorticoid receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the glucocorticoid receptor for treating or preventing diseases (e.g., obesity, diabetes, depression, neurodegeneration or an inflammatory disease) associated with glucocorticoid binding to the glucocorticoid receptor.

  本发明提供了糖皮质激素受体的非甾体配体，制备糖皮质激素受体的非甾体配体的方法，糖皮质激素受体的非甾体配体的组合物以及使用非甾体配体和糖皮质激素受体的非甾体配体的组合物治疗或预防与糖皮质激素结合到糖皮质激素受体相关的疾病（例如肥胖症，糖尿病，抑郁症，神经退行性疾病或炎症性疾病）。